Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL

NCT00520208 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Promyelocytic Leukemia

Interventions

DRUG: Tamibarotene

Sponsor

CytRx